The Pharma R&D Fact Book 2007

Table of Contents

Volume 1

Introduction

• The Cost of Developing a New Drug
• The Drug Development Process
• Regulatory Changes
• ..the situation in the US
• Post-regulation .. the Role of Watchdogs
• Generics
• The Way Forward
• Notes & Definitions
• Company Notes

DATA TABLES

• Exchange Rates (against US$)
• Country and Region of Domicile, Reporting Year-End, Currency and Revenues from Pharmaceutical Products
• Total Revenues by Company 1997-2011 (Local Currency)
• R&D Expenditure by Company 1997-2011 (Local Currency)
• Five Year Change in R&D Expenditure Ranked by Value 2002-2006
• (US$ million, at Constant 2002 Exchange Rates; Mean Change=72.5; SD=73.87)
• Five Year Change in R&D Expenditure Ranked by Percentage Change 2002-2006
• (US$ million, at Constant 2002 Exchange Rates; Mean Change=72.5; SD=73.87)
• Ten Year Change in R&D Expenditure 1997-2006
• (US$ million, at Constant 1997 Exchange Rates; Mean Change=205.6; SD=226.9)
• Predicted Change in R&D Expenditure Ranked by Value 2006-2011
• (US$ million, at Constant 2006 Exchange Rates)
• Predicted Change in R&D Expenditure Ranked by Percentage Change 2006-2011
• (US$ million, at Constant 2006 Exchange Rates)
• US Companies by R&D Expenditure by Company 2002-2006 (US$ million)
• R&D Expenditure for Top Ten US Companies
• European Companies by R&D Expenditure 2002-2006 (US$ million)
• R&D Expenditure for Top Ten European Companies
• Japanese Companies by R&D Expenditure 2002-2006 (US$ million)
• R&D Expenditure for Top Ten Japanese Companies
• Total R&D Expenditure for Featured Companies
• Research Ratio (%) by Company 1997-2011
• Five Year Change in R&D Ratio (%) Ranked by Value 2002-2006 (Mean Change=2.5; SD=5.84)
• Five Year Change in R&D Ratio (%) Ranked by Point Change 2002-2006 (Mean Change=2.5; SD=5.84)
• Ten Year Change in R&D Ratio (%) by Point Change 1997-2006 (Mean Change=1.4; SD=5.87)
• Predicted Change in R&D Ratio (%) by Value 2006-2011 (Mean Change=0.0)
• Predicted Change in R&D Ratio (%) by Point Change 2006-2011 (Mean Change=0.90)
• US Companies by Five Year Change in R&D Ratio (%) by Point Change 2002-2006 (Mean Change=2.2 SD=7.92)
• Research Ratios for Top Ten US Companies
• European Companies by Five Year Change in R&D Ratio (%) by Point Change 2002- 2006 (Mean Change=0.9; SD=2.49)
• Research Ratios for Top European Companies
• Japanese Companies by Five Year Change in R&D Ratio (%) by Point Change 2002-2006 (Mean Change=4.8; SD=2.54)
• Research Ratios for Top Ten Japanese Companies
• R&D Pipeline Summary Table 2007 - Products by Trial Phase

Abbott

• R&D PIPELINE
• INFLAMMATION
• ANTI-INFECTIVES
• NEUROSCIENCE
• VIROLOGY
• CARDIOVASCULAR
• ONCOLOGY
• GASTROINTESTINAL
• OTHERS

Alcon

• R&D PIPELINE
• OPHTHALMOLOGY
• OTIC

Allergan

• R&D PIPELINE
• NEUROSCIENCES
• OPTHTHALMOLOGY
• MEDICAL DERMATOLOGY
• OTHER

Amgen

• R&D PIPELINE
• HAEMATOLOGY
• IMMUNOLOGY
• INFLAMMATION
• ONCOLOGY
• OTHER

Astellas Pharma

• R&D PIPELINE
• CARDIOVASCULAR
• UROLOGY
• INFLAMMATION & IMMUNOLOGY
• GASTROINTESTINAL
• INFECTIOUS DISEASE
• CENTRAL NERVOUS SYSTEM
• METABOLIC
• BONE DISORDERS
• ONCOLOGY

AstraZeneca

• R&D PIPELINE
• GASTROINTESTINAL
• CARDIOVASCULAR
• NEUROSCIENCE
• CANCER
• RESPIRATORY AND INFLAMMATION
• INFECTION

Bayer

• R&D PIPELINE
• WOMEN' S HEALTHCARE
• HEMATOLOGY/CARDIOLOGY
• DIAGNOSTIC IMAGING
• SPECIALIZED THERAPEUTICS
• ONCOLOGY

Boehringer Ingelheim

• R&D PIPELINE
• RESPIRATORY
• CARDIOVASCULAR
• UROLOGY
• CENTRAL NERVOUS SYSTEM
• IMMUNOLOGY AND INFLAMMATION
• VIROLOGY
• ONCOLOGY
• METABOLIC

Bristol-Myers Squib

• R&D PIPELINE
• CARDIOVASCULAR AND METABOLIC DISEASES
• VIROLOGY
• NEUROSCIENCE
• ONCOLOGY
• IMMUNOLOGY
• OTHERS

Chugai Pharmaceutical

• R&D PIPLINE
• ONCOLOGY
• RENAL DISEASES
• TRANSPLANT, IMMUNOLOGY AND INFECTIOUS DISEASES
• BONE AND JOINT
• CARDIO/CEREBRO-VASCULAR
• OTHER

Daichi Sankyo

• R&D PIPELINE
• CARDIOVASCULAR
• METABOLISM
• INFECTION
• IMMUNITY AND ALLERGY
• BONE AND JOINTS
• CANCER
• OTHERS

Dainipon Sumitomo Pharma

• R&D PIPELINE
• CARDIOVASCULAR
• ONCOLOGY/INFECTION
• INFLAMMATION/ALLERGY
• CENTRAL NERVOUS SYSTEM
• DIABETES
• OTHER

Eisai

• R&D PIPELINE
• NEUROLOGY
• GASTROENTEROLOGY
• CARDIOVASCULAR AND RESPIRATORY
• METABOLIC
• DIAGNOSTICS
• ANTI-INFECTIVES
• ONCOLOGY
• OTHER

EliLily

• R&D PIPELINE
• NEUROSCIENCE
• ENDOCRINE DISEASES
• ONCOLOGY
• CARDIOVASCULAR
• ANTI-INFECTIVES
• OTHERS

Forest Laboratories

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
• CARDIOVASCULAR
• OTHER

Gilead

• R&D PIPELINE
• ANTI-VIRAL
• OTHERS

GlaxoSmithKline

• R&D PIPELINE
• RESPIRATORY
• NEUROSCIENCES
• ANTIVIRALS
• ANTIBACTERIALS/ANTIMALARIALS
• METABOLIC
• VACCINES
• CARDIOVASCULAR
• UROGENITAL
• ONCOLOGY AND EMESIS
• GASTROINTESTINAL
• MUSCULOSKELETAL & INFLAMMATION

Volume 2

JOHNSON & JOHNSON

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
• HAEMATOLOGY
• IMMUNOLOGY
• ANTI-INFECTIVE
• GASTROINTESTINAL
• REPRODUCTIVE HEALTH
• ONCOLOGY
• CARDIOVASCULAR
• OTHER

KYOWA HAKKO

• R&D PIPELINE
• ANTI-ALLERGY
• CENTRAL NERVOUS SYSTEM
• ANTICANCER
• GASTROINTESTINAL
• OTHERS

LUNDBECK

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM

MERCK KGAA

• R&D PIPELINE
• NEUROLOGY
• CARDIOMETABOLIC CARE
• METABOLISM
• REPRODUCTIVE HEALTH
• ONCOLOGY
• AUTOIMMUNE / INFLAMMATORY
• OTHER

MERCK & CO

• R&D PIPELINE
• CARDIOVASCULAR
• RESPIRATORY
• ANTI-INFLAMMATORY
• VACCINES & BIOLOGICALS
• ANTIBACTERIALS/ANTIFUNGALS
• OPHTHALMOLOGICAL
• UROLOGY
• NEUROLOGY
• METABOLIC
• ONCOLOGY
• HIV
• OTHERS

MITSUBISHI PHARMA

• R&D PIPELINE
• CIRCULATORY SYSTEM AND METABOLISM
• NEUROPSYCHIATRY
• RESPIRATORY SYSTEM AND IMMUNOLOGY
• ONCOLOGY AND HEPATOLOGY
• OTHER

NOVARTIS

• R&D PIPELINE
• CARDIOVASCULAR AND METABOLISM
• ONCOLOGY/HAEMATOLOGY
• NEUROSCIENCE
• ARTHRITIS/BONE
• GASTROINTESTINAL
• RESPIRATORY/DERMATOLOGY
• TRANSPLANTATION/IMMUNOLOGY
• INFECTIOUS DISEASES
• OPHTHALMICS

NOVO NORDISK

• R&D PIPELINE
• DIABETES CARE
• BIOPHARMACEUTICALS

NYCOMED

• R&D PIPELINE
• PAIN
• RESPIRATORY
• OTHERS

OTSUKA

• R&D PIPELINE
• CARDIOVASCULAR
• GASTROINTESTINAL
• CENTRAL NERVOUS SYSTEM
• ANTICANCER
• ANTI-INFECTIVE
• RESPIRATORY
• OTHERS

PFIZER

• R&D PIPELINE
• CARDIOVASCULAR / METABOLISM
• CENTRAL NERVOUS SYSTEM
• INFECTIOUS AND RESPIRATORY
• UROLOGY
• ARTHRITIS AND PAIN
• ONCOLOGY
• OPHTHALMOLOGY
• ENDOCRINE DISORDERS
• WOMEN' S HEALTHCARE
• OTHER

PROCTER & GAMBLE

• R&D PIPELINE
• MUSCUOLOSKELETAL
• GASTROINTESTINAL
• CARDIOVASCULAR

RECORDATI

• R&D PIPELINE
• CARDIOVASCULAR
• CENTRAL NERVOUS SYSTEM
• GASTROENTEROLOGY/UROLOGY
• RESPIRATORY
• ANTI-INFECTIVES
• OTHERS

ROCHE

• R&D PIPELINE
• ONCOLOGY
• VIROLOGY/INFECTIOUS DISEASES
• INFLAMMATORY, AUTOIMMUNE AND TRANSPLANTATION
• METABOLISM & BONE
• ANAEMIA
• CARDIOVASCULAR
• CENTRAL NERVOUS SYSTEM
• RESPIRATORY
• OPHTHALMOLOGY
• OTHERS

SANOFI-AVENTIS

• R&D PIPELINE
• CARDIOVASCULAR / THROMBOSIS
• ONCOLOGY
• CENTRAL NERVOUS SYSTEM
• METABOLISM / DIABETES
• VACCINES
• RESPIRATORY / ALLERGY
• ARTHRITIS / OSTEOPOROSIS
• GENITO-URINARY
• ANTI-INFECTIVE
• OTHER

SCHERING-PLOUGH

• R&D PIPELINE
• ALLERGY & RESPIRATORY
• ANTIVIRAL
• ANTI-INFLAMMATORY
• ONCOLOGY
• ANTI-INFECTIVES
• CARDIOVASCULAR
• OTHERS

SHIONOGI

• R&D PIPELINE
• INFECTIOUS DISEASES
• METABOLIC SYNDROME
• ANTICANCER
• NEUROLOGY
• ALLERGY
• CIRCULATORY SYSTEM
• OTHER

SOLVAY

• R&D PIPELINE
• CARDIOMETABOLICS
• WOMEN' S AND MEN' S HEALTH
• NEUROSCIENCE
• PANCREATIC ENZYMES
• INFLUENZA VACCINES
• OTHERS

TAKEDA

• R&D PIPELINE
• METABOLIC
• CARDIOVASCULAR
• GASTROINTESTINAL
• ANTICANCER
• MUSCULOSKELETAL
• CENTRAL NERVOUS SYSTEM
• OTHERS

TANABE

• R&D PIPELINE
• CARDIOVASCULAR AND RESPIRATORY SYSTEM
• CENTRAL AND PERIPHERAL NERVOUS SYSTEM
• IMMUNOLOGY AND INFLAMMATION
• OTHERS

UCB

• R&D PIPELINE
• CENTRAL NERVOUS SYSTEM
• IMMUNO-ALLERGOLOGY
• ONCOLOGY
• OTHERS

WYETH

• R&D PIPELINE
• NEUROSCIENCE
• GASTROENTEROLOGY
• VACCINES
• MUSCULOSKELETAL
• WOMEN' S HEALTHCARE / CONTRACEPTION
• ANTI-INFECTIVES
• IMMUNOLOGY
• ONCOLOGY
• CARDIOVASCULAR & METABOLIC DISORDERS
• OTHERS